Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University’s Medical Sciences Business Development & Partnering team reflect on 2018 and look forward to 2019

The Business Development & Partnering team standing together surrounded by festive Christmas decoration

2018 was a landmark year for the Divisional Business Development and Partnering Team. In addition to strengthening our research alliances with UCB, Novo Nordisk, Celgene, Pfizer and Bayer, we also saw some important strategic developments. We were delighted to welcome Novo Nordisk to Oxford in the summer, with the opening of the Novo Nordisk Oxford Research Centre based on the Old Road Campus which will strengthen our research partnership. The summer also saw the opening of the BioEscalator, a hub for new and developing life science innovations.

We were thrilled to learn that Innovate UK and industry are to invest more than £17.5 million in the University of Oxford to develop artificial intelligence (AI) healthcare applications. Funding will be provided through the Government’s Industrial Strategy Challenge Fund by as part of a £50 million investment to establish a network of digital pathology, imaging and AI centres, to drive innovation in the use of AI for improved diagnosis and delivery of precision treatments.

We have continued to deliver a range of events to engage our research community with industry, including the 2018 AIMday in Biomedical Imaging which was a huge success and we hope to repeat this in 2019 with a new AIMday in Advanced Therapies and Regenerative Medicine.

More recently, the Oxford MIT Healthcare Technologies of the Future Conference saw the University of Oxford and MIT come together to strengthen and share our industry networks and highlight some of our spin outs.

We are delighted to have developed, delivered and supported so many alliances, collaborations, opportunities and events in 2018 and look forward to a successful and fruitful 2019.

Find out more about the Business Development Team

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.